CLINICAL ACTIVITY AND PHARMACOKINETICS (PK) OF CABOZANTINIB (XL184) IN PATIENTS WITH PROGRESSIVE MEDULLARY THYROID CARCINOMA (MTC)

被引：0
|
作者：
Cohen, E. E. W. [1 ]
Elisei, R. [2 ]
Schlumberger, M. J. [3 ]
Mueller, S. P. [4 ]
Schoeffski, P. [5 ]
Brose, M. [6 ]
Shah, M. [7 ]
Miles, D. R. [8 ]
Nguyen, L. T. [8 ]
Sherman, S. [9 ]
机构：
[1] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[2] Univ Pisa, Dept Endocrinol, Pisa, Italy
[3] Inst Canc Res, Villejuif, France
[4] Univ Klinikum Essen, Klin & Poliklin Nukl Med, Essen, Germany
[5] Univ Hosp Leuven, Dept Gen Med Oncol, Louvain, Belgium
[6] Univ Penn Hlth Syst, Dept Med, Philadelphia, PA USA
[7] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[8] Exelixis Inc, Nonclin Dev, San Francisco, CA USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disord, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：154 / 155
页数：2
相关论文
共 50 条
  • [41] Disease severity and results of surgery in patients with medullary thyroid carcinoma (MTC)
    Pulatova, Nargiza
    Ismalov, S. I.
    HORMONE RESEARCH, 2006, 65 : 32 - 32
  • [42] Medullary thyroid carcinoma (MTC) - clinical and molecular aspects on the basis of own experience
    Pomorski, L
    Bartkowiak, J
    Pisarek, H
    Bartos, M
    Narebski, J
    NEOPLASMA, 2000, 47 (05) : 323 - 326
  • [43] Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial
    Shih, Chie-Schin
    Blakeley, Jaishri
    Clapp, D. Wade
    Armstrong, Amy E.
    Wolters, Pam
    Dombi, Eva
    Cutter, Gary
    Ullrich, Nicole J.
    Allen, Jeffrey
    Packer, Roger
    Goldman, Stewart
    Gutmann, David H.
    Plotkin, Scott
    Rosser, Tena
    Robertson, Kent
    Widemann, Brigitte
    Rhodes, Steven
    Angus, Steven
    Johnson, Gary
    Korf, Bruce
    Fisher, Michael J.
    CANCER RESEARCH, 2019, 79 (13)
  • [44] Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM)
    DePrimo, S.
    Wu, B.
    Huang, S.
    Bautista, R.
    Cancilla, B.
    Vysotskaia, V.
    De Groot, J.
    Prados, M.
    Buller, R.
    Wen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] HYPOCALCEMIC ACTIVITY OF SERUM IN PATIENTS WITH MEDULLARY CARCINOMA OF THYROID
    STEPHENS, CL
    BRAUNSTEIN, H
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1969, 52 (02) : 170 - +
  • [46] Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB)
    Wen, P. Y.
    Prados, M.
    Schiff, D.
    Reardon, D. A.
    Cloughesy, T.
    Mikkelsen, T.
    Batchelor, T.
    Drappatz, J.
    Chamberlain, M. C.
    De Groot, J. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Prevalence and Clinical Spectrum of Nonsecretory Medullary Thyroid Carcinoma in a Series of 839 Patients with Sporadic Medullary Thyroid Carcinoma
    Frank-Raue, Karin
    Machens, Andreas
    Leidig-Bruckner, Gudrun
    Rondot, Susanne
    Haag, Christine
    Schulze, Egbert
    Lorenz, Angela
    Kreissl, Michael C.
    Dralle, Henning
    Raue, Friedhelm
    Schmid, Kurt W.
    THYROID, 2013, 23 (03) : 294 - 300
  • [48] Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier
    Randolph, Gregory W.
    Sosa, Julie Ann
    Hao, Yangyang
    Angell, Trevor E.
    Shonka, David C., Jr.
    LiVolsi, Virginia A.
    Ladenson, Paul W.
    Blevins, Thomas C.
    Duh, Quan-Yang
    Ghossein, Ronald
    Harrell, Mack
    Patel, Kepal Narendra
    Shanik, Michael H.
    Traweek, S. Thomas
    Walsh, P. Sean
    Yeh, Michael W.
    Ahmed, Amr H. Abdelhamid
    Ho, Allen S.
    Wong, Richard J.
    Klopper, Joshua P.
    Huang, Jing
    Kennedy, Giulia C.
    Kloos, Richard T.
    Sadow, Peter M.
    THYROID, 2022, 32 (09) : 1069 - 1076
  • [49] CABOZANTINIB (XL184) AT 40 MG IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): RESULTS OF A PHASE 2 NON-RANDOMIZED EXPANSION COHORT (NRE)
    de Bono, J. S.
    Smith, M. R.
    Rathkopf, D.
    Corn, P. G.
    Mukherji, D.
    Harzstark, A. L.
    Sartor, O. A.
    Smith, D. C.
    Tunariu, N.
    Sweeney, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 296 - 296
  • [50] Potent antitumor activity of XL184 (cabozantinib), a c-MET and VEGFR2 inhibitor, in colorectal cancer patient-derived tumor explant models.
    Atreya, Chloe E.
    Song, Eun-Kee
    Messersmith, Wells
    Purkey, Alicia
    Bagby, Stacey
    Quackenbush, Kevin
    Kelley, Robin K.
    Kwak, Eunice
    Ryan, David
    Venook, Alan
    Arcaroli, John J.
    CANCER RESEARCH, 2013, 73 (08)
12345